Together, these results demonstrated that chidamide potentiated YAP1 expression, selectively inhibited cell survival, and the combination of chidamide and FLT3 inhibitors or chemotherapy agents displayed more lethality in acquired resistant FLT3-ITD+ AML cells ex vivo. This evidence concerns the gene YAP1 and acute myeloid leukemia.